Navigation Links
Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
Date:10/1/2011

LAS VEGAS, Oct. 1, 2011 /PRNewswire/ -- This information is being released by SCM:

Dr. Arthur Reingold, witness for the defense in the second hepatitis C trial in Nevada, was called to the stand today offering expert testimony as an epidemiologist. During questioning by the defense, Dr. Reingold testified transference of the deadly virus hepatitis C could have occurred from a lack of hand washing, ungloved hands, bite blocks, biopsy equipment, gowns and aprons, and that cross contamination of bacteria may have occurred on a daily basis. 

(Photo:  http://photos.prnewswire.com/prnh/20111001/LA78785)

When cross examined by lead trial attorney for the plaintiffs, Robert Eglet, Dr. Reingold responded to questions about his testimony concerning transmission of hepatitis C at the Endoscopy Center of Southern Nevada.

"You can not state with certainty or to any reasonable degree of medical probability or have any evidence that the GI techs or any specific person was not wearing gloves, or that ungloved hands were the cause of transmission of the hepatitis C virus, or that the CRNAs were not washing their hands or wearing gowns or aprons that may have served as the source of the transmission of hepatitis C to Anne Arnold?" said Eglet. "No," stated Reingold. So you are not saying that hepatitis C on an apron somehow found its way into the bloodstream of Anne Arnold, Correct?" said Eglet. "Yes," stated Reingold.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

This is the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected. In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs. 


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Lehigh University leads Department of Defense MURI grant for atomic-scale interphase research
4. Winners of inaugural defense fellowships to further research at NTU
5. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
6. Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defenses Net Zero Energy Initiative
7. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
8. TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs
9. NJIT physicist sees terahertz imaging as ultimate defense against terrorism
10. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
11. UCLA gets $5.5 million from Defense agency to create new rotating microscale motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president and ... Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will be among ... Dinner. , The dinner recognizes women accomplished in science, technology, engineering and math ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):